Czech company Synthesia celebrate Gelita shipment

First oxidized cellulose left Synthesia in final medical device packaging (06.06.2007)
We shipped the first completely packed delivery of oxidized cellulose to our customer! So far deliveries have left Synthesia not finally packed, but as raw material intended for further processing. Production of finally packed product is a major milestone in Synthesia´s history.
In the future only finally packed product will be leaving Synthesia´s gates. It is packed in a primary and secondary packaging, intended for use on operating rooms, labeled by trademark of our exclusive partner and worldwide distributor company called Gelita Medical. Gelitacel is distributed directly to end users, surgeons in hospitals worldwide. Click here and find more information on oxidized cellulose.

King Pharmaceuticals Acquires License from Gelita Medical to Hemostatic Products

King Pharmaceuticals, Inc. (NYSE:KG) and Gelita Medical BV announced today that the companies have entered into an exclusive license agreement relating to Gelita’s absorbable gelatin hemostatic products.

Pursuant to the agreement, King received an exclusive license to market, distribute and sell Gelita’s absorbable gelatin sponge in the U.S. Gelita will manufacture and supply the hemostatic product to King under the agreement. King’s THROMBIN-JMI® (thrombin, topical, bovine, USP), a topical active hemostatic agent, is often used by surgeons together with a variety of passive hemostatic agents, including absorbable gelatin sponges.

Brian A. Markison, President and Chief Executive Officer of King, stated, “The addition of Gelita’s absorbable gelatin hemostatic agents to our product line will further strengthen our expanding portfolio of hospital products. Importantly, this transaction further enhances the wide array of hemostatic options that our hospital sales team of over 110 professionals can offer physicians for the purpose of controlling bleeding during surgery.” Dr. Harrie van Baars, CEO of Gelita Medical, stated, “With King we have attracted an excellent and well focused marketing partner for our products in the U.S. market.”

King plans to begin marketing Gelita’s absorbable gelatin sponge in the U.S. after the product receives approval from the U.S. Food and Drug Administration for use during surgery. The license also provides King an exclusive option to acquire U.S. commercialization rights to any new hemostatic products developed by Gelita. The companies did not provide financial details relating to the transaction.

Dr. Harrie Van Baars of the Netherlands, CEO Gelita Medical, was previously CEO of Curamedical he also is also linked to company CircumventBV and the circumcision device the Smartklamp
Click Here for action Gelita is taking against Equicel
Link to FDA letter for Gelita approval Here

Collagen Based Hemostats

Davol Inc., a subsidiary of C. R. Bard Inc., develops, manufactures, and markets Avitene Microfibrillar Collagen Hemostat and Ultrafoam™ Collagen Sponge, topical hemostatic agents, and other specialty medical products for use in surgical procedures worldwide.

J&J (Ethicon) Collagen Hemostat for precise application. Controlled application minimizes product waste. Handles easily without sticking to wet gloves or instruments.

Gelita Medical The FDA has classified Pharmaceutical Gelatin as GRAS (Generally Recognized As Safe) and it has been used in over 200 million procedures.

Vascular Solutions D-Stat Flowable is a thick, yet flowable hemostat designed for topical application to stop bleeding at vascular access sites following percutaneous procedures.

Orthovita Vitagel is composed of microfibrillar collagen and thrombin in combination with the patient’s own plasma which contains fibrinogen and platelets.

B Braun Lyostypt® is a wet-stable collagen hemostat. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII. Therefore, collagen is very effective in hemostasis